Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
To explore the key comprehensive nursing points for 21 patients with recurrent IgA nephropathy after kidney transplantation during treatment with telitacicept, summarize effective nursing measures, so as to improve treatment safety and patient prognosis, and provide reference for the nursing of similar clinical cases.
A retrospective analysis was conducted on the clinical nursing data of 21 patients with recurrent IgA nephropathy after kidney transplantation who received telitacicept treatment. The nursing measures included: ① Pre-treatment assessment: Comprehensive examination of liver and kidney function, infection indicators (such as virus and bacterial infection screening), evaluation of patients' psychological status and medication compliance, and targeted health education (such as drug effects and possible adverse reactions); ② Intra-treatment nursing: Strictly administering drugs as prescribed by doctors, closely monitoring infusion reactions (such as fever and rash), regularly rechecking blood routine, liver and kidney function and urinary protein indicators, and focusing on infection prevention (such as guiding patients to avoid crowded places and pay attention to personal hygiene); ③ Individualized intervention: Conducting psychological counseling for patients with anxiety, formulating dietary plans according to the characteristics after transplantation (such as low-salt and high-quality protein diet), and guiding patients to maintain regular work and rest and avoid overwork.
All 21 patients completed the preset course of telitacicept treatment. During the treatment, 2 cases had mild adverse reactions (2 cases of mild skin allergic reactions, which were relieved by ice compress), and no serious complications such as severe infection or acute deterioration of renal function occurred. After treatment, the serum creatinine and 24-hour urine protein quantification of patients were significantly improved compared with those before treatment (P<0.05), their psychological status tended to be stable, and the treatment compliance reached 100%.
For patients with recurrent IgA nephropathy after kidney transplantation receiving telitacicept treatment, the implementation of a comprehensive nursing model of "comprehensive pre-treatment assessment +Intra-treatment nursing+ individualized intervention" can effectively reduce adverse reactions, ensure the smooth progress of treatment, and promote the improvement of renal function, which has clinical promotion value.
